Premium
Multiple applications of flurbiprofen and chlorhexidine chips in patients with chronic periodontitis: a randomized, double blind, parallel, 2‐arms clinical trial
Author(s) -
Machtei Eli E.,
Hirsh Ilan,
Falah Maher,
Shoshani Eyal,
Avramoff Avi,
Penhasi Adel
Publication year - 2011
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/j.1600-051x.2011.01779.x
Subject(s) - medicine , scaling and root planing , chronic periodontitis , periodontitis , randomized controlled trial , chlorhexidine , gingival recession , dentistry , bleeding on probing , double blind , gastroenterology , nuclear medicine , placebo , pathology , alternative medicine
Aim The aim of the present randomized, double blind, parallel, 2‐arm clinical study was to examine the safety and efficacy of frequent applications of chlorhexidine chip ( CHX ) and flurbiprofen chip ( FBP ) in patients with chronic periodontitis. Methods Sixty patients were randomized into CHX and FBP groups. Following OHI and scaling and root planing ( SRP ), baseline pocket depth ( PD ) measurements, gingival recession and bleeding on probing ( BOP ) were performed and repeated at week 4 and 8. The assigned chip was placed at weeks 0, 1, 2, 3, 5, 7. Results Mean PD reduction in the CHX group was 2.08 mm (7.17 to 5.09, p < 0.0001). Mean PD reduction in the FBP group was 2.27 mm (6.72 to 4.45, p < 0.0001). Ninety‐seven percentage and 95% of these sites exhibited PD reduction ≥1 mm, while 38% and 34% of the sites exhibited PD ≥3 mm ( FBP and CHX , respectively). Clinical attachment level gain (1.66 and 1.95 mm, respectively) was statistically significant ( p < 0.0001). Baseline BOP dropped from 98% and 100% to 24% and 30% for the CHX and FBP groups, respectively ( p < 0.0001). Conclusion Frequent applications of CHX and FBP chips resulted in a significant improvement in the periodontal condition in these sites. Furthermore studies will be required to compare this new treatment regimen to SRP or SRP with single chip application.